Noy-25-2008 C8:13pm From-cooper&dunham

T-297 P.007/009 F-020 +212 391 0525

Douglas J. M. Allen et al. 10/716,098 Applicants:

Serial No.:

: November 17, 2003 Filed

Page 4

TNT

cancer, breast cancer, ovarian cancer, prostate cancer, or colorectal cancer.

(Canceled) 24.

- (Previously Presented) The method of claim 23 further 25. comprising administering to said mammal a therapeutically effective amount of a compound selected from the group consisting of alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell-cycle inhibitor, enzymes, topoisomerase, inhibitors, anti-hormones, and anti-androgens.
- 26. (Previously Presented) The method of claim 25 wherein the cell-cycle inhibitor is a mitotic inhibitor.
- The pharmaceutical composition 27. (Previously Presented) of claim 16, comprising from about 0.001 mg-to about 100 mg/kg/day N-(ethynylphenyl)-6,7-bis(2-menhoxyethoxy)-4-Exam. Amdt. pharmaceutically mesylate and a 12/1/08 quinazolinamine acceptable carrier.
 - The pharmaceutical composition 28. (Previously Presented) of claim 16, comprising from about 0.001-mg-to about 100 mg/kg/day of a hydrate form of N-(ethynylphenyl)-6,7-bis(2methoxyethoxy)-4-quinazolinamine mesylate and a pharmaceutically acceptable carrier.

PAGE 7/9 * RCVD AT 11/25/2008 8:22:24 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/44 * DNIS:2738300 * CSID:+2123910525 * DURATION (mm-ss):01-16